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Intestinal Behçet’s disease (intestinal BD) is a rare chronic inflammatory disorder of the intestine that is characterized by re-
current intestinal manifestations with other systemic features of BD. Intestinal BD is diagnosed when a typically shaped ulcer 
is observed in the gastrointestinal tract, and the clinical findings meet the diagnostic criteria for BD. Owing to the small number 
of patients, intestinal BD is easily underestimated. On the other hand, but it often requires surgical treatment because of severe 
complications, including intestinal perforations or massive bleeding. The same treatment strategies used for inflammatory bow-
el diseases, such as Crohn’s disease and ulcerative colitis, are used for intestinal BD. 5-Aminosalicylic acids, corticosteroids, 
and immunomodulators are considered conventional therapies, but a considerable number of patients eventually become un-
responsive to these pharmaceutical treatments. Recently, biologic agents, such as anti-tumor necrosis factor-alpha inhibitors, 
have also been suggested as a new treatment option for intestinal BD. This article reviews the pathogenesis and diagnosis of 
intestinal BD and the current treatment strategies that are expected to be useful for rheumatologic specialists. (J Rheum Dis 
2021;28:4-16)
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INTRODUCTION
Behçet’s disease (BD) is a chronic and relapsing disorder 
that causes multisystemic inflammation. The disease was 
named after the Turkish dermatologist Hulûsi Behçet, 
who described BD for the first time in 1937 in patients 
with symptoms consisting of aphthous oral ulcers, geni-
tal ulcers, and iritis [1]. BD is rare in Western countries 
but is relatively prevalent in East Asia, Middle East Asia, 
and the Mediterranean region. In general, BD involves or-
al and genital ulcers and vascular and ocular manifestations. 
Occasionally, it can also occur in joints, central nervous 
system, and gastrointestinal tract. Intestinal BD is de-
fined when a patient diagnosed with BD has prevalent in-
testinal symptoms and typical ulcerations observed on an 
endoscopic examination [2,3]. Among patients with BD, 
up to 5%∼10% are diagnosed with intestinal BD [4,5].
Similar to BD, the causes of intestinal BD are not com-
pletely understood, but genetic, immunologic, and envi-
ronmental factors appear to be associated with the 
disease. The major symptoms of intestinal BD include ab-
dominal pain, diarrhea, severe hematochezia, and even 
intestinal perforation. The symptoms and clinical courses 
are heterogeneous, ranging from mild to severe, and sev-
eral patients show a poor prognosis. The demand for nov-
el therapy and clinical trials is high because it is currently 
incurable, but relatively few studies have been conducted 
because of its low prevalence. Despite this limitation, 
clinical studies have been conducted [4]. Another aspect 
of intestinal BD is its similarity to inflammatory bowel 
disease (IBD). These two diseases share the same genetic 
background, pathogenesis, treatment strategies, and clin-
ical outcomes. Hence, gastroenterologists often classified 
them as the same disease entity. Based on studies on the 
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Figure 1. Diagnosis of intestinal Behçet’s disease (BD) (adapted from the article of Cheon et al. Am J Gastroenterol 
2009;104:2492-9 [10]). *Single or few deep oval-shaped ulcers with discrete margins in the ileocecal area, †aphthous, shallow 
ulcers.
pathogenesis of immune-related diseases and clinical 
similarity of these two diseases, the therapeutic arma-
mentarium for intestinal BD has been developed in ac-
cordance with that for IBD. 
On the other hand, there is a critical demand for elabo-
rate therapeutic strategies for intestinal BD because it fre-
quently fails to respond to conventional therapies and is 
a long-standing disease requiring large amounts of 
medications. Moreover, BD is handled mainly by rheuma-
tologists, whereas the gastroenterologists have more ex-
perience with patients with intestinal involvement of BD. 
Accordingly, intestinal BD, which has overlapping parts 
in terms of vasculitis and intestinal pathologies, requires 
cooperative care that can integrate expertise between 
rheumatology and gastroenterology under a systemic 
communication route. This review article provides 
up-to-date information for rheumatologist readers on the 
pathogenesis and treatment options for intestinal BD 
from the perspective of a gastroenterologist. 
MAIN SUBJECTS
Behçet’s disease and intestinal Behçet’s disease
BD is difficult to confirm because no definitive diag-
nostic biomarker has been identified, and the related 
symptoms often develop asynchronously. Moreover, in-
testinal BD is more complicated because of its similarity 
to other illnesses, such as Crohn’s disease and intestinal 
tuberculosis. Thus, a differential diagnosis is important 
for deciding the therapeutic approach for intestinal BD. 
The diagnostic criteria for BD recommended by the BD 
research committee of Japan in 1987 have been used 
widely and consist of four major and five minor symp-
toms [6]. In 1990, the International Study Group for 
Behçet’s Disease also recommended the diagnostic cri-
teria, which include recurrent oral ulceration and the 
presence of any two of the following clinical manifes-
tations: genital ulcers, skin lesions, eye involvement, and 
positive pathergy reaction [7]. Traditionally, BD and in-
testinal BD are diagnosed based on subjective symptom 
assessments, which are often challenging and dependent 
on the clinicians’ experience. For a long time, intestinal 
BD was diagnosed when BD patients with predominantly 
gastrointestinal symptoms showed intestinal ulcerations 
on endoscopic and radiological examinations [3].
On the other hand, a delayed diagnosis is prevalent be-
cause not all patients with intestinal BD show systemic 
symptoms at the time of the endoscopic examination [8] 
because these symptoms may appear several years after 
the patient’s first experience of intestinal discomfort [9]. 
To overcome these limitations, novel diagnostic criteria 
have been recommended by the Korean Association for 
the Study of Intestinal Diseases using the modified 
Delphi process, which is now commonly used in clinical 
trials and patient treatment [10]. In accordance with 
these criteria, intestinal BD can be diagnosed when ulcer-
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ation in the terminal ileum or inflammation in the small 
or large intestine is found along with clinical manifes-
tations that satisfy the diagnostic criteria of BD. These 
clinical findings are particularly useful for diagnosing pa-
tients whose symptoms do not fully meet the diagnostic 
criteria for systemic BD at the initial presentation. 
Basically, a diagnosis of intestinal BD relies on a combina-
tion of clinical, endoscopic, pathological, and radiological 
findings [11]. The clinical manifestations are similar to 
those of IBD, including diarrhea, hematochezia, weight 
loss, and abdominal pain with tenderness on the affected 
area [12]. The typical endoscopic features are oval-shap-
ed large intestinal ulcerations in the ileocecal area with 
deep and discrete borders [8]. These features can vary 
from aphthous to deep penetrating volcano-shaped ulcer-
ations and ulcerations with a more frequently focal to less 
frequently diffuse distribution [13]. The pathological 
findings in patients with intestinal BD are vasculitis in-
volving the small and medium-sized vessels; lymphocyte 
infiltration in the perivascular space can also be detected 
[14,15]. Figure 1 presents the recommended diagnostic 
algorithm, which includes endoscopic observations and 
systemic BD criteria [10].
In diseases with unknown etiologies and no accurate di-
agnostic biomarkers, such as BD or IBD, the level of in-
flammation cannot be easily measured using a single 
parameter. Hence, a disease activity scoring system is 
needed to monitor the inflammatory status objectively 
and confirm the disease severity. The BD activity indices 
usually include the severity, location, and extent of the 
disease, and complications [16]. For intestinal BD, a sim-
ple and validated measurement tool called the Disease 
Activity Index of intestinal Behçet’s disease (DAIBD) was 
proposed in 2011 by the Korean IBD Study Group for an 
assessment of the disease activity and establishing a ther-
apeutic plan [17]. Before the development of the DAIBD, 
the Crohn’s disease activity index (CDAI) had been used 
for intestinal BD owing to the similarities between the 
two diseases [3]. The DAIBD involves eight categories: 
general condition, extraintestinal manifestations, fever, 
abdominal pain, abdominal mass, abdominal tenderness, 
intestinal complications, and frequent liquid stools. The 
items are rated, with total scores ranging from 0 to 325. 
The disease is categorized as quiescent, mild, moderate, 
and severe disease based on the total score (≤19, 20∼39, 
40∼74, and ≥75, respectively). The DAIBD is highly 
weighted on the general well-being and abdominal pain 
rather than on the other indices. Although the DAIBD is 
not correlated significantly with the endoscopic severity 
[18], it is more responsive and shows a better correlation 
with the physician’s global assessment score than CDAI. 
Further studies will be needed in various ethnicities and 
for the validation of DAIBD regarding whether it can pre-
dict the disease course precisely based on endoscopic ex-
aminations and clinical symptoms.
1) Recent findings of genetic and immune responses in 
intestinal BD
Insights into the roles of genetic and immune responses 
in disease development or prognosis along with the de-
velopment of molecular biological research techniques, 
including the genome-wide association studies (GWASs) 
and next-genome sequencing (NGS), have changed medi-
cal practice significantly [19]. The clinical symptoms and 
genetic features between intestinal BD and BD or IBD 
overlap; some genetic features of intestinal BD overlap 
with IBD, while others overlap with BD. A human leukocyte 
antigen (HLA)-B51 allele and MHC class I-related gene A 
(MICA) are well-known genetic factors of BD [20-24], 
which have not been identified in IBD. In contrast, the re-
cently identified factors, namely interleukin (IL) 10 and the 
IL23R-IL12RB2 loci, are associated with BD and IBD 
[21,25]. The recent findings from Korean patients with 
intestinal BD suggest that IL17A, IL23R, and STAT4 SNPs 
modulate the susceptibility to intestinal BD. In particular, 
the haplotype of IL17A was observed to be a risk factor for 
intestinal BD development, whereas that of IL23R was as-
sociated with disease protection [26]. GWASs on in-
testinal BD first elucidated the genetic polymorphisms 
that contribute to disease development. They showed 
that NAALADL2 and YIPF7 have strong associations with 
the intestinal inflammation risk, thereby allowing the dif-
ferentiation of intestinal BD from BD without intestinal 
involvement.
Regarding the contribution of the immunological re-
sponse to triggering inflammation, similar to those in 
other autoimmune diseases, increased levels of Th1, 
Th17, CD4+, and CD8+ T cell, and γδ+ T cell activities, as 
well as IL-12 and tumor necrosis factor alpha (TNF-α) 
levels, were elevated in patients with BD [27-32]. Most of 
the proinflammatory cytokines associated with the innate 
immune system are activated in Crohn’s disease and ul-
cerative colitis. This finding also applies to intestinal BD 
and has therapeutic implications. In patients with IBD, 
increasing numbers or activation of innate immune cells, 
including neutrophils, macrophages, and natural killer T 
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Figure 2. Treatment algorithm based on the disease severity (adapted from the article of Lee et al. Intest Res 2013;11:155-60 [39]).
DAIBD: Disease Activity Index of intestinal Behçet’s disease, 5-ASA: 5-Aminosalicylic acids, AZA: azathioprine, 6-MP: 6-mercap-
topurine, MTX: methotrexate, IMM: immunomodulator.
cells, and adaptive immune cells, such as B and T cells, in-
crease in the levels of TNF-α, IL-1β, interferon (IFN)-γ, 
and cytokines in the IL-23–Th17 pathway [33]. As with 
Crohn’s disease, Th1- and Th17-related cytokines (IL-12, 
IL-23, and IL-27) are also upregulated in BD [34]. A re-
cent study reported that the IL-12B levels correlated with 
the clinical and endoscopic disease activities of intestinal 
BD and IBD [35]. Proteomic analysis showed that the 
IL-1β and serum amyloid A levels were markedly higher 
in patients with intestinal BD [36]. These explanations of 
the pathophysiology of intestinal BD and the genet-
ic/clinical overlap between intestinal BD and IBD lead to 
a wide range of changes in the therapeutic environment of 
intestinal BD.
2) Principles of the therapeutic approach
Owing to the rarity of intestinal BD, scrutinized or sys-
tematic prospective clinical trials have not been preva-
lently conducted. Empirical and evidence-based ther-
apeutic approaches have been established based on sev-
eral retrospective studies and the similar pathophysio-
logical background between intestinal BD and Crohn’s 
disease, but the choice of treatment is still dependent on 
the physicians’ opinion [4]. In this regard, Japanese re-
searchers published consensus statements for the diag-
nosis and standard therapy for intestinal BD in 2007 [3]. 
Revised versions of the statements were published in 
2014 [37] and 2020 [38], including the statement that an 
anti-TNF inhibitor can be considered standard therapy. 
The treatment algorithm, according to the disease se-
verity, has been proposed based on the accumulated stud-
ies and experts’ opinions in 2013 [39]. Considering the 
latest clinical trials and published data, this paper sug-
gests an up-to-date treatment algorithm as follows 
(Figure 2). Basically, it is similar to the treatment proce-
dure in the step-up therapy for IBD according to the dis-
ease severity (mild to moderate or severe) aiming to ach-
ieve and maintain clinical remission [40]. This is a se-
quential treatment procedure that is usually initiated by 
generally tolerable medications, such as 5-amino-
salicylates, with escalation to the more effective but po-
tentially more toxic drugs, including immunomodulators 
and biologics, for patients in whom each previous step of 
therapy has failed. With this algorithm, patients can avoid 
overtreatment and the unnecessary risk of adverse 
events, particularly in cases of a tolerable standard 
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therapy. In IBD treatment, the top-down therapy strategy 
was proposed to induce rapid clinical remission with 
highly effective medications, such as early biologics, but 
no such attempts or research studies have been per-
formed for intestinal BD. Surgery should be considered in 
a timely manner when the patient is suspected of severe 
complications or does not respond properly to the medi-
cal treatment. Complications, even irreversible ones, are 
likely to occur in accordance with a delayed decision of 
surgical intervention. Hence, the close discussion be-
tween gastroenterologists and surgeons is required. 
Therefore, a multidisciplinary approach should be avail-
able whenever their expertise is demanded in the in-
testinal BD treatment.
3) 5-Aminosalicylic acids
5-Aminosalicylic acids (5-ASA) have a similar mecha-
nism to aspirin or non-steroidal anti-inflammatory drugs, 
which target the COX-2-inducing immunomodulatory 
actions to reduce intestinal inflammation [41]. 5-ASA in-
hibits COX-2 expression resulting from TNF-α/IL-1β 
[42]. The 5-ASAs used widely for IBD treatment, espe-
cially for patients with ulcerative colitis, are mesalamine, 
mesalazine, or sulfasalazine [43]. The clinical dosages of 
5-ASA in patients with intestinal BD usually range from 2 
to 4 g/day, while sulfasalazine is generally administered 
at 3 to 4 g/day [4]. Several clinical studies have obtained 
inconsistent results regarding the effectiveness of 5-ASA 
for intestinal BD. A case series study that included pa-
tients with intestinal BD reported that 79% patients 
showed symptomatic or colonoscopic improvement with 
sulfasalazine therapy [44]. A large-scale retrospective 
study conducted in 2012 showed that 5-ASA/sulfasala-
zine monotherapy was effective in maintaining re-
mission, specifically with cumulative relapse rates of 
46.7% at 10 years after remission. Younger age, disease 
severity, and higher C-reactive protein (CRP) level were 
associated with a poor prognosis with 5-ASA/sulfasala-
zine therapy [45]. A recent study investigated the in-
duction response rate of oral 5-ASA and showed response 
and remission rates of 61% and 57%, respectively, at 
week 8 [46]. Thus, 5-ASA can be recommended as in-
duction and maintenance therapies for relatively mild to 
moderate intestinal BD. Conclusively, 5-ASA is a sub-
stantial therapeutic option that needs to be used in al-
most all patients with intestinal BD. On the other hand, 
patients with small bowel involvement are not indicated 
for sulfasalazine use.
4) Corticosteroids
Systemic corticosteroids are used effectively to control 
flare-ups in patients with moderate to severe BD and IBD 
in cases of failure of 5-ASA/sulfasalazine treatment 
[47-49]. Corticosteroids, which are well-known fast-act-
ing anti-inflammatory drugs, are used widely with tapering 
strategies at a starting dosage of 0.5∼1.0 mg/kg/day [3] 
that is tapered to 5 mg each week and stopped within 
three months. Well-designed prospective clinical trials on 
the effectiveness of corticosteroids in patients with in-
testinal BD have not been conducted thus far. Some retro-
spective studies have suggested that corticosteroids are 
effective in the induction phase of intestinal BD. One ret-
rospective cohort study [50] in Korea that included 54 pa-
tients reported that 46.3% (n=25) of patients with active 
intestinal BD achieved complete remission after one 
month of treatment, while 42.6% showed partial remission. 
After three months of treatment, 40.7% of the patients 
still responded to the corticosteroid treatment. One year 
after the initiation of corticosteroid administration, 
48.1% of the patients remained responsive to the treat-
ment, and 8.1% showed a prolonged response, but 35.2% 
had corticosteroid dependency, and 7.4% underwent in-
testinal surgery. Thus, it is recommended for inducing a 
short-term response in the early phase of the disease 
course, especially with severe systemic symptoms or se-
vere disease activity. Considering that patients with in-
testinal BD with high-risk factors, such as gastro-
intestinal bleeding, mainly use this medication, side ef-
fects are the main burden for both physicians and patients 
because they increase the risk of gastrointestinal bleeding 
and perforation [51]. In addition, corticosteroid therapy 
was strongly associated with rebleeding in patients with 
intestinal BD (hazard ratio [HR], 3.2; 95% confidence in-
terval, 1.070∼9.462; p=0.037) [52]. Therefore, a taper-
ing dose strategy should be maintained, and the pro-
longed use of prednisolone must not exceed 10 mg/day. 
Systemic corticosteroids are often used too easily without 
hesitation, even if there are no symptoms. Moreover, they 
are often prolonged in clinical practice. Steroid usage 
should be based rigorously on the overall symptoms, and 
should not be used unconditionally due only to the pres-
ence of intestinal ulcers.
5) Immunomodulators
(1) Thiopurines
Thiopurine analogs, consisting of 6-mercaptopurine 
(6-MP) and its derivate, azathioprine (AZA), are func-
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tioning antimetabolites of nucleic acids that were in-
troduced to inhibit the growth of rapidly dividing cells in 
the 1950s [53]. Thiopurines require an extensive metab-
olism to form thioguanine nucleotides (TGNs) because 
they are prodrugs that act specifically via the following 
three pathways: (1) inactivation of 6-MP to thiouric acid 
by xanthine oxidase and aldehyde oxidase, (2) 6-methyl 
MP (6-MMP) production by thiopurine methyltransfer-
ase (TPMT), (3) conversion of 6-MP to 6-TGN by en-
zymes, such as TPMT, inosine monophosphate dehydrogen-
ase, and hypoxanthine phosphoribosyl transferase 
[54,55]. Regarding the mechanism of action of thio-
purines, TPMT plays a major role in producing inactive 
6-MMP and active 6-TGN by generating 6-methyl MP ri-
bonucleotide (6-MMPR), and can ultimately increase 
6-TGN production by converting 6-thioinosine mono-
phosphate to 6-MMR indirectly [56]. The anti-inflammatory 
action of thiopurine is achieved by 6-TGN. In particular, it 
is integrated into leukocyte DNA and prevents DNA syn-
thesis, which inhibits downstream T-cell proliferation 
and immunosuppression [57]. Based on this metabolism, 
AZA/6-MP is commonly indicated for patients with mod-
erate to severe intestinal BD, specifically those who are 
refractory or dependent on corticosteroids or show a sec-
ondary loss of response to anti-TNF-α agents. The drug 
is also used to reduce the postoperative recurrence rate 
after intestinal surgery [58].
AZA (25 to 50 mg/day) is effective for both the cellular 
and humoral immune responses, particularly for the ini-
tial dose indication, in patients with intestinal BD. The 
dose can be increased gradually every 2 to 3 weeks up to 
2.0 to 2.5 mg/kg, unless adverse drug reactions occur, 
such as leukopenia [59]. Although only one retrospective 
cohort study was conducted in patients with intestinal 
BD treated with AZA, it established the benefit of AZA as 
maintenance therapy. Jung et al. [59] evaluated 272 pa-
tients with intestinal BD who received thiopurine mono-
therapy and reported that 58.2% (39/67) of patients who 
received the first course of thiopurine remained in re-
mission with thiopurine maintenance therapy. In this 
study, the cumulative relapse rates at 1, 2, 3, and 5 years 
after remission were 5.8%, 28.7%, 43.7%, and 51.7%, 
respectively. Younger age (＜25 years) at diagnosis and 
lower hemoglobin level (＜11 g/dL) were associated with 
a poor prognosis.
Similarly, Lee at al. [58] reviewed the postoperative re-
currence rate of intestinal BD in patients who received 
thiopurine treatment, and the cumulative rate of clinical 
recurrence after surgery was significantly lower in the thi-
opurine group than in the 5-ASA treatment group (p= 
0.050). Moreover, the HR of postoperative thiopurines 
compared to 5-ASA was 0.636 (range, 0.130∼1.016; 
p=0.053) for postoperative recurrence. AZA is an effec-
tive treatment for intestinal inflammation and can be 
used stably in the long term unless side effects occur. The 
most common and serious side effect is leukopenia, 
which increases the infection risk and even mortality 
[60]. Thus, the American Gastroenterological Association 
recommends that patients treated with AZA should be 
monitored routinely with complete blood counts [61].
With regard to IBD treatment, a genotype-based strat-
egy for thiopurine treatment using the TPMT, FTO, and 
NUDT15 variants to prevent and reduce myelosup-
pression was investigated [62]. Including intestinal BD 
patients, that prospective study assigned seventy-two pa-
tients randomly to a group with genotype analysis 
(NUDT15 variant, FTO variant, TPMT variants) and a 
non-genotyping group. Myelosuppression was more fre-
quent in the non-genotyping group than the pretreatment 
genotype analysis group (35.9%, 16.7%, respectively, 
p=0.005). Recognizing genetic information in advance 
and adjusting the treatment plans also led to a decrease in 
the numbers and frequencies of outpatient clinic visits, 
drug discontinuation, and dose reductions [62]. Azathioprine 
is a beneficial therapeutic option, but it is still difficult to 
use for patients with hematological disorders, such as 
aplastic anemia and myelodysplastic syndrome (MDS), 
because of the potential side effects. Further prospective 
randomized placebo-controlled trials with more patients 
will be necessary for elucidating a safer thiopurine treat-
ment for patients with intestinal BD.
(2) Methotrexate
Methotrexate (MTX) is an analog of folic acid and ami-
nopterin that was first manufactured in 1945 and is a 
long-standing medication that has been used for patients 
with cancer since the 1950s [63]. Recently, it has gained 
renewed attention as a notable therapy for autoimmune 
diseases. Low-dose MTX (25 mg/day for the induction 
phase) appears to be effective in the treatment of rheuma-
toid arthritis, neuro-BD, uveitis, and other types of BD in-
volvement [64-66]. In addition, MTX is used increasingly 
in combination with biologics owing to the immuno-
genicity of anti-TNF inhibitors [67]. The mechanism of 
immunosuppression by MTX mainly involves the reduc-
tion of cell proliferation, an increase in the rate of apopto-
sis of T-cells, and endogenous adenosine accumulation. 
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Hence, it can alter cytokine production, humoral re-
sponses, and bone formation, which leads to the deactiva-
tion of the immune system [68]. The effectiveness and 
safety of MTX for intestinal BD have rarely been 
investigated. A case series of 10 patients with refractory 
intestinal BD reported improved symptoms and dis-
ease-related complications within four weeks of MTX 
treatment in 2011 [69]. Moreover, the ulcers disappeared 
in nine of the patients at 12 months. 
Park et al. [70] published retrospective data on the effi-
cacy of MTX therapy, specifically MTX monotherapy and 
combination therapy with MTX and adalimumab (ADA), 
for intestinal BD in 2018. Among 10 patients, three and 
five attained steroid-free remission at three and six 
months, respectively. The serum CRP level, erythrocyte 
sedimentation rate, and DAIBD score decreased at six 
months compared to their baseline values, but only the 
decrease in CRP levels was statistically significant (p= 
0.039) [70].
(3) Other immunomodulators
Immunomodulators, including cyclosporine, tacroli-
mus, interferon (IFN), and intravenous immunoglobulin 
(IVIG), are considered alternative therapeutic options for 
intestinal BD based on their pharmaceutical mechanism. 
On the other hand, no sufficient scientific evidence exists 
because of the relatively few cases reported, and no pro-
spective clinical trials of immunomodulators have been 
conducted in patients with intestinal BD. Cyclosporine, 
which decreases the levels of inflammatory cytokines in 
T-lymphocytes by blocking the phosphatase activity of 
calcineurin [71], is commonly used for autoimmune dis-
eases, such as rheumatoid arthritis, psoriasis, and ocular 
manifestations of BD [72,73]. According to the updated 
European League Against Rheumatism guideline, nerv-
ous system involvement is not indicated for cyclosporine 
based on level 3 evidence [74]. Bayraktar et al. [75] and 
the unpublished experience from Severance Hospital sug-
gest that cyclosporine therapy has no clinical benefit for 
patients with intestinal BD. Tacrolimus, a macrocyclic 
lactone with potent immunosuppressive properties [76], 
is a standard immunosuppressive regimen after renal 
transplantation [77]. One case was reported, and clinical 
improvement was observed in patients with intestinal BD 
refractory to conventional therapies [78]. IFN and IVIG 
were introduced in the 1950s and have been used for ar-
thritis, BD [79,80], and other autoimmune diseases.
On the other hand, studies examining the role of these 
therapies in intestinal BD are limited. Therefore, the effi-
cacy of IFN or IVIG for intestinal BD is unclear. A study of 
patients with BD who were unresponsive to systemic ste-
roids and/or immunosuppressants was conducted using 
subcutaneous IFN‐α at a dosage of 6×106 IU/day three 
times per week for two months. In that study, 75% (9/12) 
of the patients achieved complete remission, 16.6% 
(2/12) had partial remission, and 8.3% showed no re-
sponse [81]. In 1998, a 32-year-old Caucasian woman 
with intestinal BD was treated with IVIG. Her symptoms 
improved after IVIG treatment initiation, and the in-
testinal lesions disappeared after six weeks of IVIG ther-
apy at 400 mg/kg/day for five days [82]. Nevertheless, 
further evidence and clinical trials will be needed to prove 
their efficacy.
6) Thalidomide
Thalidomide was first used as a sedative in the 1950s 
and withdrawn from the European pharmaceutical mar-
ket in the 1960s owing to its teratogenic effects in early 
pregnancy, including severe birth defects, such as phoco-
melia [83]. This was defined as a “thalidomide tragedy” 
and has been a major issue in the history of biomedical 
ethics and drug safety monitoring. Eventually, it con-
tributed to the approval system and toxicology guidelines 
of the United States Food and Drug Administration 
[84,85]. After several clinical trials over a decade, thalido-
mide has now been approved and used for the treatment 
of inflammatory diseases, including leprosy, rheumatoid 
arthritis, BD, and even multiple myeloma or malignant 
B-cell lymphoma [86-88]. Thalidomide, a synthetic de-
rivative of glutamic acid, was suggested to be effective 
against the mucocutaneous and follicular lesions of BD 
based on the results of a randomized, double-blind, place-
bo-controlled study [89]. A case series of BD with in-
testinal involvement reported that thalidomide was effec-
tive for recurrent perforating intestinal ulcers and led to 
clinical improvement in terms of corticosteroid-free re-
mission [90,91]. 
These outcomes were observed consistently in another 
case series in Korea [92]. Patients with recurrent in-
testinal BD refractory to conventional treatments, includ-
ing 5-ASA and immunomodulators, reported a response 
to thalidomide with clinical and radiological improvement. 
The major side effects observed were edema, neu-
tropenia, and sepsis. Similarly, a prospective open-label 
study of patients with IBD treated with thalidomide re-
ported clinical response rates of 83.3% and 100.0% for 
Crohn’s disease and ulcerative colitis at week 12 [93]. 
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Definitive dose guidelines for intestinal BD are not 
available. On the other hand, an initial thalidomide dos-
age of 2 mg/kg/day has been used, and dose adjustment 
according to the treatment response is needed [90]. In ad-
dition, thalidomide appears to exert a selective effect on 
TNF‐α production by the degradation of its encoding 
messenger RNA [94]. Thus, the efficacy and safety of an-
ti-TNF inhibitor or thalidomide therapy were inves-
tigated in patients with intestinal BD who were refractory 
to conventional therapies [95]. Of 13 patients, 10 (75%) 
achieved clinical and endoscopic remission with TNF-α 
antagonists and/or thalidomide therapy. This result also 
supports the efficacy of thalidomide as a therapeutic op-
tion for intestinal BD. Nevertheless, well-designed pro-
spective trials are still needed, and rigorous monitoring of 
the side effects is warranted.
7) Biologics
While recent advances in the novel therapeutic arma-
mentarium, including biologics for autoimmune dis-
eases, have made transformative changes in therapeutic 
environments. Several biologic agents are now available 
for patients with autoimmune diseases, particularly those 
who do not respond to conventional therapies or those 
who develop serious adverse events. The use of these bio-
logics has also been attempted in patients with intestinal 
BD. As mentioned previously, the pathogenesis of in-
testinal BD is related to an abnormal T-cell immune re-
sponse and cytokines derived from T helper type 1 (Th1) 
lymphocytes, including TNF-α, IFN-γ, IL-12, and IL-18 
[96,97]. The TNF-α expression level in the blood in-
creases, mucosal damage occurs, and clinical symptoms 
worsen [98]. Therefore, biologics targeting TNF-α have 
been administered to patients with intestinal BD with 
these scientific backgrounds. Currently, anti-TNF-α 
monoclonal antibodies, including infliximab (IFX) and 
ADA, are considered standard therapies for patients with 
intestinal BD [37].
(1) Infliximab
IFX, a TNF blocker, is indicated for patients with IBD, ar-
thritis, ankylosing spondylitis, and psoriasis, and who 
have shown an inadequate response to conventional ther-
apy [4]. A dose of 5 mg/kg at zero, two, and six weeks is 
suggested for induction therapy and then every eight 
weeks for maintenance therapy. Some adult patients who 
respond initially to treatment may benefit from increas-
ing the dose to 10 mg/kg if they later become un-
responsive to this treatment [37]. The first case report of 
IFX use for intestinal BD was in 2001, which showed a de-
creased CDAI score from 270 to 13 points by week two, 
and endoscopic and histological improvements at week 
10 [99]. The following case reports consistently sug-
gested the positive efficacy of IFX for intestinal BD as 
both induction and maintenance therapy [100,101]. A 
multicenter retrospective study in patients with moder-
ate to severe intestinal BD reported the results of IFX 
treatment from 28 patients in Korean tertiary hospitals 
[102]. The clinical response rates at 2, 4, 30, and 54 weeks 
were 75%, 64.3%, 50%, and 39.1%, respectively, and the 
clinical remission rate at week 30 was 46.2%. During the 
follow-up period, one case of serious infection was ob-
served, but no malignancies or deaths occurred. The effi-
cacy and safety of IFX were investigated in a prospective 
open-label phase 3 study in 2016, which included 18 pa-
tients with BD. Among the patients enrolled, 11 had in-
testinal involvement and were refractory to conventional 
therapies [103]. The IFX dose was the same as that for 
Crohn’s disease and ulcerative colitis. A complete re-
sponse was observed in 61% (11/18) of patients at weeks 
14 and 30, and the patients remained in remission until 
week 54. The CRP levels were decreased after week two, 
and most of the subjects showed healed ulcers at week 14. 
Despite these results, as with patients with IBD, the pa-
tients with intestinal BD in this study also showed a pri-
mary and secondary loss of response. Hence, the need to 
increase the dose at week 30 or treatment failure were ob-
served [103]. An interventional, open-label, single-arm, 
multicenter study of IFX in 33 patients with moderate to 
severe refractory intestinal BD is ongoing in Korea 
(ClinicalTrials.gov NCT02505568). This study is ex-
pected to provide more scientific evidence for the effec-
tiveness of IFX treatment for patients with intestinal BD. 
Studies are still lacking, but evidence for the positive effi-
cacy of IFX combination therapy with immunomo-
dulators has been reported. In a previous study [69], all 
10 patients showed improvement in the intestinal symp-
toms and complications within four weeks. The rate of 
disappearance of ileocecal ulcerations was 50% (5/10) 
and 90% (9/10) at 6 and 12 months, respectively [69]. 
Combination therapy of biologics with immunomodulators 
is beneficial for reducing the immunogenicity and in-
creasing the serum levels, but the risks of infection and 
malignancy need to be considered carefully [104].
(2) Adalimumab
ADA is a fully human anti-TNF-α monoclonal antibody, 
whereas IFX is a chimeric monoclonal antibody against 
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TNF-α. The doses for patients with intestinal BD can be 
used for induction therapy at doses of 160, 80, and 40 mg 
at week zero (baseline), two, and four subcutaneously, 
and then 40 mg every other week for responders [105]. 
De Cassan et al. [106] described their experience with 
ADA use as the first anti-TNF-α inhibitor in two patients 
with familial intestinal BD, who were steroid dependent. 
Rapid clinical remission was observed in the induction 
phase, which was sustained in the maintenance phase. 
The following case report suggested the efficacy of ADA 
for intestinal BD with myelodysplastic syndrome based 
on successful improvement in gastrointestinal symp-
toms, CRP levels, leukocytopenia, and anemia four 
months after the ADA treatment [107]. After that, a pro-
spective multicenter open-label study was conducted in 
Japan that involved 20 patients with intestinal BD, who 
were refractory to conventional therapies, such as corti-
costeroids or immunomodulators [105]. Nine patients 
(45%) achieved the primary endpoints after 24 weeks, 
which were an alleviation of gastrointestinal symptoms 
and a decrease in the endoscopic assessment score to 1 or 
lower than the baseline score. In addition, ADA treat-
ment induced complete remission in 20% of patients at 
week 24, which was maintained until week 52, but no no-
table safety issues were observed. A recent phase 3 study 
in Japan evaluated the efficacy and long-term safety pro-
files of ADA treatment in 20 patients with intestinal BD. 
Fifteen of the patients remained in the study until 100 
weeks of follow-up. Significant improvement, which was 
defined based on the gastrointestinal symptom and endo-
scopic scores, was observed in 60% of patients at week 52 
and 40% at week 100. Of the patients, 20% and 15% 
showed clinical remission at weeks 52 and 100, re-
spectively, with tolerable safety profiles [108]. These re-
sults played a pivotal role in gaining approval of the use of 
ADA for intestinal BD treatment in Japan. Combination 
therapy using ADA with other immunomodulatory medi-
cations has not yet been actively investigated. Vitale et al., 
however, compared the efficacy and safety of ADA mono-
therapy and combination therapy with disease-modifying 
antirheumatic drugs. In this study, 100 patients with BD 
were enrolled; no significant difference in clinical out-
comes was observed between the two groups [109]. 
A study in 2019 examined the effectiveness of anti-TNFs 
in patients with intestinal BD compared to that of cortico-
steroids without anti-TNF. Both groups showed improve-
ment in the DAIBD score one year after treatment 
(85.2±29.6 to 40.5±44.7 in the corticosteroid group and 
64.7±34.9 to 21.1±28.9 in the anti-TNF group). 
Anti-TNF administration was effective in reducing the 
concomitant steroid dose to ＜7.5 mg (p=0.0001). 
Considering that one patient discontinued treatment be-
cause of bacterial infection, the potential risk of intestinal 
perforation or massive bleeding should be considered 
when using steroids [110]. A recently published study 
that used real-world data on ADA and IFX for patients 
with refractory intestinal BD suggested switching from 
an anti-TNF inhibitor to another if a patient is refractory 
to the first-line anti-TNF inhibitor [111]. Biologics can be 
ineffective in cases of urgent patients who require surgi-
cal intervention. Therefore, a decision should be made 
under a multi-disciplinary discussion, including gastro-
enterologists, rheumatologists, and surgeons, as to wheth-
er to discontinue the treatment and perform surgery.
CONCLUSION
The prevalence of intestinal BD is low in Western coun-
tries but relatively high in East Asian countries, including 
Korea. Thus, there are limited clinical trial data with in-
testinal BD due to the general lack of disease awareness, 
small number of cases, and difficulty in subject recruitment. 
In addition, it is a relapsing, complex systemic in-
flammatory disease that is often unpredictable and has a 
“wax and wane” disease course with massive bleeding 
and perforation. Patients are easily refractory to conven-
tional therapies, which caused new biologics to evolve in 
the treatment of intestinal BD. Intestinal BD can be treat-
ed using the same therapeutic approaches for BD, but the 
differences in intestinal BD from other types of BD in 
terms of the intestinal specific pathophysiology and treat-
ment response must be considered. Thus far, the IBD 
treatment guidelines are effective in the treatment of in-
testinal BD. Several retrospective studies or clinical trials 
with a small number of patients have been the mainstay 
for gathering evidence on intestinal BD treatment. On the 
other hand, recent prospective and scientifically designed 
clinical trials specifically for intestinal BD have actively 
been conducted. Therefore, an effective treatment guide-
line is expected to be established soon. As for biologics, 
many novel agents with different targets have emerged 
for autoimmune diseases, including IL 12/23, Janus kin-
ases, and IL-6 inhibitors. Further clinical research focus-
ing on intestinal BD will be needed to obtain scientific 
evidence and provide treatment opportunities to the 
patients. Ultimately, close cooperation between rheuma-
Management of Intestinal Behçet’s Disease
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tology, gastroenterology, and colorectal surgery depart-
ments as multidisciplinary care is essential for the treat-
ment of intestinal BD.
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